About Vista Pharmaceuticals Ltd.
Data last updated: 23 December 2025
Vista Pharmaceuticals Ltd. is a public limited company based in Na, Telangana, India. It specialises in drug formulation and development, a part of the broader pharmaceuticals sector. Incorporated on 25 January 1991, the company has been in operation for over 35 years.
Registered with ROC Hyderabad under CIN L24239TG1991PLC012264. Listed on BSE: 524711.
Capital: an authorised share capital of ₹15 Cr and a paid-up capital of ₹12.31 Cr. It is led by directors including Mallem Hanumantha Rao and Pavan Sathvik Gilaka.
Last AGM: 30 September 2024. Financial statements filed for year ended 31 March 2024. Office: Na, Telangana.
As per the financials filed for FY 2024, the company reported a revenue of ₹10.62 Cr, reflecting significant growth compared to the previous year.
The company is associated with 1 brand - Vista Pharmaceuticals. As per MCA filings, the company has open charges of ₹17 Cr and satisfied charges of ₹16.08 Cr on record.
The current compliance status is marked as compliant by the Registrar of Companies. For more details, the company can be reached via its website vistapharmaceuticals.com.
-
Email*****@*****.com
-
Telephone+91-****-******
-
Website
-
Social Media**************
-
Registered AddressPlot Nos.10 To 14 And 16 To 20 Apiic Industrial Estate Chityal Gop, Alaipalli, Na, Telangana, India – 508254
-
IndustryPharma, Drug Formulation & Development
- Historical Financials and ratios
- Shareholding pattern and group structure
- Charges with holder and property details
- Litigation, compliance and MCA filings
- PDF report delivered after checkout
CIN History of Vista Pharmaceuticals Ltd.
Vista Pharmaceuticals Ltd. has one previous CIN (Corporate Identification Number): L24239AP1991PLC012264. The current CIN is L24239TG1991PLC012264, which is the unique identifier assigned by the Registrar of Companies.
| CIN | Status |
|---|---|
| L24239TG1991PLC012264 | Current |
| L24239AP1991PLC012264 | Previous |
Associated Brands with Vista Pharmaceuticals Ltd.
Vista Pharmaceuticals Ltd. operates one associated brand: Vista Pharmaceuticals. These brands represent Vista Pharmaceuticals Ltd.'s diversified market presence and brand portfolio.
| Brand | Description | Website |
|---|---|---|
| Manufacturer of OTCs and generic prescription products | vistapharmaceuticals.com |
Business Activity of Vista Pharmaceuticals Ltd.
Vista Pharmaceuticals Ltd. is engaged in the principal business activity of manufacturing, with detailed activities including chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products.
| Main Activity Group Code | Description of Main Activity | Business Activity Code | Description of Business Activity | Turnover Percentage |
|---|---|---|---|---|
| C | Manufacturing | C6 | Chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products | ********* |
Auditor Details of Vista Pharmaceuticals Ltd.
Vista Pharmaceuticals Ltd. is audited by A M REDDY & DR REDDY (ICAI peer reviewed, certificate valid till 2027-02-28) for the financial year 2026, as reported in its BSE exchange filings. The statutory auditor is responsible for expressing an independent opinion on whether the financial statements present a true and fair view in accordance with applicable accounting standards.
| Name | Financial year | Audit opinion |
|---|---|---|
| A M REDDY & DR REDDY (ICAI peer reviewed, certificate valid till 2027-02-28) | FY 2026 | Declaration of unmodified opinion |
Board of Directors of Vista Pharmaceuticals Ltd.
Vista Pharmaceuticals Ltd. is currently managed by 11 directors, with 17 former directors having served the organization. The current Directors play a crucial role in shaping the company's strategic direction and governance.
| Name | Designation | Appointment Date | Tenure | Status |
|---|---|---|---|---|
| Mallem Hanumantha Rao | Director | 16 Sep 1993 | 32 Years 9 Months | Current |
|
Pavan Sathvik Gilaka
Also directs:
Mavone Infrastructure Private Limited
|
Whole-Time Director | 14 Oct 2022 | 3 Years 8 Months | Current |
| Divakar Reddy Yerrabommanahalli | Director | 30 Sep 2019 | 6 Years 9 Months | Current |
| Stanley Prabhakar Reddy | Director | 12 Aug 2016 | 9 Years 10 Months | Current |
| Umesh Virupakah Banakar | Director | 24 Feb 2018 | 8 Years 4 Months | Current |
| Divya Bhavani Chakravarthula | Director | 24 Feb 2018 | 8 Years 4 Months | Current |
Financials of Vista Pharmaceuticals Ltd. FY 2026 filings available
Vista Pharmaceuticals Ltd. reported revenue of ₹5.4 Cr (down 46.4% YoY) for FY 2026. Profit growth despite declining revenue indicates effective cost management and margin discipline.
| Metrics | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|---|
| Revenue from Operations | ₹5.4 Cr | ₹10.07 Cr | ₹10.29 Cr | ₹1 Cr | ₹39.46 Lakh | ₹1.27 Cr | ₹22.76 Cr | ₹31.07 Cr |
| Other Income | ₹31.5 Lakh | ₹44.06 Lakh | ₹33.34 Lakh | ₹28.55 Lakh | ₹16.57 Lakh | ₹31.85 Lakh | ₹3.75 Cr | ₹2.95 Cr |
| Total Income | ₹5.71 Cr | ₹10.52 Cr | ₹10.62 Cr | ₹1.29 Cr | ₹56.03 Lakh | ₹1.58 Cr | ₹26.51 Cr | ₹34.02 Cr |
| Cost of Materials Consumed | ₹5.22 Cr | ₹7.9 Cr | ₹8.88 Cr | ₹1.23 Cr | ₹36.66 Lakh | ₹73.02 Lakh | ₹22.9 Cr | ₹26.81 Cr |
| Purchases of Stock-in-Trade | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 |
| Changes in Inventories | ₹0 | ₹44.78 Lakh | ₹77,000 | ₹0 | ₹0 | ₹0 | ₹1.04 Cr | -₹1.4 Cr |
| Employee Benefit Expense | ₹2.2 Cr | ₹2 Cr | ₹1.79 Cr | ₹58.19 Lakh | ₹57.48 Lakh | ₹1.15 Cr | ₹1.49 Cr | ₹1.36 Cr |
| Finance Costs | ₹1.1 Cr | ₹96.4 Lakh | ₹1.22 Cr | ₹1.21 Cr | ₹89.98 Lakh | ₹1.55 Cr | ₹1.54 Cr | ₹1.67 Cr |
| Depreciation & Amortisation | ₹74.89 Lakh | ₹73.81 Lakh | ₹71.97 Lakh | ₹1.57 Cr | ₹61.62 Lakh | ₹72.77 Lakh | ₹1.35 Cr | ₹1.36 Cr |
| Other Expenses | ₹12.59 Cr | ₹3.75 Cr | ₹3.17 Cr | ₹1.41 Cr | ₹66.37 Lakh | ₹1.11 Cr | ₹2.13 Cr | ₹3.06 Cr |
| Total Expenses | ₹21.87 Cr | ₹15.81 Cr | ₹15.8 Cr | ₹6.01 Cr | ₹3.12 Cr | ₹5.27 Cr | ₹30.44 Cr | ₹32.87 Cr |
| Profit Before Exceptional Items & Tax | -₹16.15 Cr | -₹5.29 Cr | -₹5.18 Cr | -₹4.72 Cr | -₹2.56 Cr | -₹3.69 Cr | -₹3.94 Cr | ₹1.15 Cr |
| Exceptional Items | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 |
| Profit Before Tax | -₹16.15 Cr | -₹5.29 Cr | -₹5.18 Cr | -₹4.72 Cr | -₹2.56 Cr | -₹3.69 Cr | -₹3.94 Cr | ₹1.15 Cr |
| Total Tax Expense | -₹4.09 Cr | -₹64.11 Lakh | -₹66.54 Lakh | ₹2.15 Cr | -₹1.73 Cr | -₹1.8 Cr | -₹25.89 Lakh | ₹20.78 Lakh |
| Net Profit | -₹12.06 Cr | -₹4.65 Cr | -₹4.51 Cr | -₹5.82 Cr | -₹83.18 Lakh | -₹1.89 Cr | -₹3.68 Cr | ₹93.94 Lakh |
| Other Comprehensive Income | ₹45,000 | -₹2.11 Lakh | ₹29,000 | -₹1.42 Lakh | ₹0 | ₹0 | ₹0 | ₹0 |
| Total Comprehensive Income | -₹12.06 Cr | -₹4.67 Cr | -₹4.51 Cr | -₹5.83 Cr | -₹83.18 Lakh | -₹1.89 Cr | -₹3.68 Cr | ₹93.94 Lakh |
| EBITDA (computed) | -₹14.3 Cr | -₹3.59 Cr | -₹3.24 Cr | -₹1.94 Cr | -₹1.04 Cr | -₹1.41 Cr | -₹1.05 Cr | ₹4.19 Cr |
| Basic EPS | ₹-1.96 | ₹-0.79 | ₹-1.03 | ₹-1.58 | ₹-0.24 | ₹-0.63 | ₹-1.22 | ₹0.31 |
| Diluted EPS | ₹-1.96 | ₹-0.79 | ₹-0.74 | ₹-0.92 | ₹-0.24 | ₹-0.63 | ₹-1.22 | ₹0.31 |
| Metrics | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|---|
| Total Assets | ₹55.08 Cr | ₹60.29 Cr | ₹57.98 Cr | ₹56.53 Cr | ₹55.59 Cr | ₹50.85 Cr | ₹51.12 Cr | ₹52.76 Cr |
| Non-current Assets | ₹39.72 Cr | ₹45.53 Cr | ₹34.58 Cr | ₹35.62 Cr | ₹40.24 Cr | ₹35.62 Cr | ₹29.94 Cr | ₹29.31 Cr |
| Current Assets | ₹15.36 Cr | ₹14.76 Cr | ₹23.4 Cr | ₹20.92 Cr | ₹15.34 Cr | ₹15.24 Cr | ₹21.19 Cr | ₹23.45 Cr |
| Property, Plant & Equipment | ₹8.71 Cr | ₹9.15 Cr | ₹9.77 Cr | ₹10.19 Cr | ₹9.78 Cr | ₹10.38 Cr | ₹11.11 Cr | ₹12.45 Cr |
| Inventories | ₹11.01 Cr | ₹8.22 Cr | ₹6.79 Cr | ₹9.28 Cr | ₹9.33 Cr | ₹9.68 Cr | ₹9.68 Cr | ₹11.25 Cr |
| Trade Receivables | ₹31.66 Lakh | ₹3.39 Cr | ₹14.28 Cr | ₹6.27 Cr | ₹2.57 Cr | ₹2.17 Cr | ₹10.28 Cr | ₹8.35 Cr |
| Cash & Equivalents | ₹10.7 Lakh | ₹1.05 Lakh | ₹9.44 Lakh | ₹0 | ₹7.19 Lakh | ₹14.01 Lakh | ₹22.52 Lakh | ₹86.77 Lakh |
| Equity (Net Worth) | ₹36.44 Cr | ₹45.42 Cr | ₹40.46 Cr | ₹36.54 Cr | ₹35.45 Cr | ₹32.85 Cr | ₹29.64 Cr | ₹35.8 Cr |
| Equity Share Capital | ₹12.31 Cr | ₹12.31 Cr | ₹9.43 Cr | ₹7.36 Cr | ₹7.36 Cr | ₹7.36 Cr | ₹6.07 Cr | ₹6.07 Cr |
| Borrowings (Non-current) | ₹1.84 Cr | ₹2.38 Cr | ₹2.93 Cr | ₹5.18 Cr | ₹15.95 Cr | ₹8.69 Cr | ₹5.51 Cr | ₹5.96 Cr |
| Borrowings (Current) | ₹8.14 Cr | ₹5.02 Cr | ₹5.03 Cr | ₹4.65 Cr | ₹99.98 Lakh | ₹6.28 Cr | ₹9.96 Cr | ₹5.21 Cr |
| Total Debt (computed) | ₹9.99 Cr | ₹7.4 Cr | ₹7.96 Cr | ₹9.83 Cr | ₹16.95 Cr | ₹14.98 Cr | ₹15.47 Cr | ₹11.17 Cr |
| Current Liabilities | ₹16.65 Cr | ₹12.37 Cr | ₹14.49 Cr | ₹14.76 Cr | ₹4.12 Cr | ₹9.25 Cr | ₹15.92 Cr | ₹10.95 Cr |
| Total Liabilities | ₹18.64 Cr | ₹14.87 Cr | ₹17.52 Cr | ₹19.99 Cr | ₹20.14 Cr | ₹18.01 Cr | ₹21.48 Cr | ₹16.96 Cr |
| Metrics | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
| Operating Cash Flow | -₹4.4 Cr | -₹6.98 Cr | -₹4.92 Cr | -₹1.72 Cr | -₹1.13 Cr |
| Investing Cash Flow | -₹78.21 Lakh | -₹44 Lakh | -₹78.99 Lakh | -₹1.27 Cr | -₹1.43 Lakh |
| Financing Cash Flow | ₹4.56 Cr | ₹8.06 Cr | ₹5.59 Cr | ₹2.99 Cr | ₹1.07 Cr |
| Capital Expenditure | ₹78.21 Lakh | ₹12.39 Lakh | ₹78.99 Lakh | ₹1.27 Cr | ₹1.43 Lakh |
| Free Cash Flow (computed) | -₹5.18 Cr | -₹7.11 Cr | -₹5.71 Cr | -₹2.99 Cr | -₹1.14 Cr |
| Dividends Paid | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 |
| Net Change in Cash | -₹62.62 Lakh | ₹63.89 Lakh | -₹11.28 Lakh | ₹7,000 | -₹6.81 Lakh |
| Metrics | Q4 FY26 | Q3 FY26 | Q2 FY26 | Q1 FY26 | Q4 FY25 | Q3 FY25 | Q2 FY25 | Q1 FY25 |
|---|---|---|---|---|---|---|---|---|
| Revenue from Operations | ₹0 | ₹2.42 Cr | ₹1.46 Cr | ₹1.52 Cr | ₹3.23 Cr | ₹2.56 Cr | ₹2.49 Cr | ₹1.8 Cr |
| Other Income | ₹3.28 Lakh | ₹8.98 Lakh | ₹19.24 Lakh | ₹0 | ₹24.06 Lakh | ₹12.19 Lakh | ₹70,100 | ₹7.11 Lakh |
| Total Income | ₹3.28 Lakh | ₹2.51 Cr | ₹1.65 Cr | ₹1.52 Cr | ₹3.47 Cr | ₹2.68 Cr | ₹2.5 Cr | ₹1.87 Cr |
| Cost of Materials Consumed | ₹0 | ₹2.26 Cr | ₹1.46 Cr | ₹1.5 Cr | ₹2.69 Cr | ₹2.05 Cr | ₹1.55 Cr | ₹1.6 Cr |
| Purchases of Stock-in-Trade | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 |
| Changes in Inventories | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹44.78 Lakh | ₹0 | ₹0 |
| Employee Benefit Expense | ₹49.87 Lakh | ₹58.98 Lakh | ₹56.8 Lakh | ₹54.24 Lakh | ₹56.02 Lakh | ₹51.54 Lakh | ₹47.87 Lakh | ₹44.97 Lakh |
| Finance Costs | ₹55.27 Lakh | ₹17.74 Lakh | ₹17.78 Lakh | ₹19.3 Lakh | ₹20.63 Lakh | ₹22.26 Lakh | ₹25.26 Lakh | ₹28.25 Lakh |
| Depreciation & Amortisation | ₹18.72 Lakh | ₹18.71 Lakh | ₹19.87 Lakh | ₹17.58 Lakh | ₹18.46 Lakh | ₹18.69 Lakh | ₹18.34 Lakh | ₹18.32 Lakh |
| Other Expenses | ₹6.56 Cr | ₹2.57 Cr | ₹2.87 Cr | ₹58.92 Lakh | ₹88.71 Lakh | ₹1.06 Cr | ₹1.29 Cr | ₹51.93 Lakh |
| Total Expenses | ₹7.8 Cr | ₹5.79 Cr | ₹5.28 Cr | ₹3 Cr | ₹4.53 Cr | ₹4.48 Cr | ₹3.75 Cr | ₹3.04 Cr |
| Profit Before Exceptional Items & Tax | -₹7.77 Cr | -₹3.28 Cr | -₹3.62 Cr | -₹1.48 Cr | -₹1.06 Cr | -₹1.8 Cr | -₹1.25 Cr | -₹1.17 Cr |
| Exceptional Items | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 |
| Profit Before Tax | -₹7.77 Cr | -₹3.28 Cr | -₹3.62 Cr | -₹1.48 Cr | -₹1.06 Cr | -₹1.8 Cr | -₹1.25 Cr | -₹1.17 Cr |
| Total Tax Expense | -₹1.91 Cr | -₹96.1 Lakh | -₹1.03 Cr | -₹18.97 Lakh | ₹43.36 Lakh | -₹48.21 Lakh | -₹27.83 Lakh | -₹31.43 Lakh |
| Net Profit | -₹5.86 Cr | -₹2.32 Cr | -₹2.59 Cr | -₹1.29 Cr | -₹1.5 Cr | -₹1.32 Cr | -₹97.37 Lakh | -₹85.7 Lakh |
| Other Comprehensive Income | -₹2.93 Lakh | ₹1.33 Lakh | ₹58,000 | ₹1.47 Lakh | -₹1.24 Lakh | ₹2.63 Lakh | ₹0 | ₹41,000 |
| Total Comprehensive Income | -₹5.89 Cr | -₹2.31 Cr | -₹2.58 Cr | -₹1.28 Cr | -₹1.51 Cr | -₹1.3 Cr | -₹97.37 Lakh | -₹85.29 Lakh |
| EBITDA (computed) | -₹7.03 Cr | -₹2.92 Cr | -₹3.25 Cr | -₹1.11 Cr | -₹67.11 Lakh | -₹1.39 Cr | -₹81.61 Lakh | -₹70.56 Lakh |
| Basic EPS | ₹-0.91 | ₹-0.41 | ₹-0.42 | ₹-0.22 | ₹-0.26 | ₹-0.07 | ₹0.00 | ₹-0.15 |
| Diluted EPS | ₹-0.91 | ₹-0.41 | ₹-0.44 | ₹-0.22 | ₹-0.26 | ₹-0.07 | ₹0.00 | ₹-0.15 |
Shareholding Pattern of Vista Pharmaceuticals Ltd.
As per the shareholding pattern filed with BSE for the quarter ended Mar 2026, promoters hold 21.19%, domestic institutional investors hold 0.02%, retail and other public shareholders hold 78.79% of Vista Pharmaceuticals Ltd.. The company had 14,154 shareholders on record.
| Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | |
|---|---|---|---|---|---|---|
| Promoters | 21.19% | 21.19% | 21.19% | 21.19% | 21.19% | 21.19% |
| Public | 78.81% | 78.81% | 78.81% | 78.81% | 78.81% | 78.81% |
| Mar 2026 | Mar 2025 | Mar 2024 | |
|---|---|---|---|
| Promoters | 21.19% | 21.19% | 27.81% |
| Public | 78.81% | 78.81% | 72.19% |
| Promoter change (YoY, %pts) | +0.00 | -6.62 | - |
Charges & Borrowings of Vista Pharmaceuticals Ltd.
| Date | Lender | Amount | Status |
|---|---|---|---|
| 23 Feb 2017 | Vijaya Bank | ₹17 Cr | Open |
| 25 Jun 2015 | State Bank of India | ₹8 Cr | Satisfied |
| 02 May 2014 | Allahabad Bank | ₹4 Cr | Satisfied |
| 16 Oct 1995 | State Bank of Hyderabad | ₹1.1 Cr | Satisfied |
| 12 Sep 1994 | State Bank of Hyderabad | ₹2.08 Cr | Satisfied |
Total charge records: 6 View all charges
Employees and EPFO Compliance at Vista Pharmaceuticals Ltd.
View historical data on people associated with Vista Pharmaceuticals Ltd., including employment history and EPFO contributions.
Employee Count & EPFO Data of Vista Pharmaceuticals Ltd.
Access employee headcount trends, monthly PF payment records, EPFO establishment details, and compliance data.
GST Compliance of Vista Pharmaceuticals Ltd.
GSTIN & GST Filing Data of Vista Pharmaceuticals Ltd.
Access GSTIN registrations, state-wise filing compliance, HSN/SAC codes, and detailed goods & services data.
Credit Ratings, Litigation & Regulatory Alerts for Vista Pharmaceuticals Ltd.
Credit Ratings, Legal Cases & Regulatory Alerts of Vista Pharmaceuticals Ltd.
Access complete credit rating history, litigation records, regulatory alerts, and compliance data.
MSME Payment Delays by Vista Pharmaceuticals Ltd.
MSME Payment Delays by Vista Pharmaceuticals Ltd.
Track payments outstanding to micro and small enterprise vendors, as disclosed in half-yearly MSME-1 returns filed with the MCA.
Subsidiaries & Group Companies of Vista Pharmaceuticals Ltd.
Subsidiaries & Group Companies of Vista Pharmaceuticals Ltd.
See the full corporate group - holding company, subsidiaries, associates and joint ventures of Vista Pharmaceuticals Ltd. with ownership details.
MCA Filings & Documents of Vista Pharmaceuticals Ltd.
MCA Filings & Documents of Vista Pharmaceuticals Ltd.
Download official documents filed with the Ministry of Corporate Affairs - from incorporation papers to the latest annual filings.
Recent Activity on Vista Pharmaceuticals Ltd.
Recent News on Vista Pharmaceuticals Ltd.
Frequently Asked Questions about Vista Pharmaceuticals Ltd.
Vista Pharmaceuticals Ltd. is an active public limited company in the pharma sector based in Na, Telangana, India. It was incorporated on 25 January 1991 (35+ years old) and is registered under CIN L24239TG1991PLC012264. Listed on BSE: 524711.
Vista Pharmaceuticals Ltd. reported revenue of ₹10.62 Cr for FY 2024 (up 657.00% YoY).
The current directors of Vista Pharmaceuticals Ltd. are:
The primary industry of Vista Pharmaceuticals Ltd. is pharma. The company specifically operates in drug formulation and development. The company is currently active in this sector.
Yes. Vista Pharmaceuticals Ltd. is listed on BSE with code 524711.
Vista Pharmaceuticals Ltd. can be reached at the registered office: Plot Nos.10 To 14 And 16 To 20 Apiic Industrial Estate Chityal Gop, Alaipalli, Na, Telangana, India – 508254, or through the website vistapharmaceuticals.com.